Clinical Lab Expo 2013
A Hippocratic Oath for the Diagnostic Industry
Tuesday, July 30, 11:00 a.m.
Vice President, Chief Medical Informatics Officer
The United States biomedical industry has lost its way. Profits at many companies take priority over the patient, and expensive proprietary tests are being marketed despite lack of clinical evidence and the existence of more cost-effective alternatives. This presentation will describe ways that hospitals and laboratories can hold their suppliers accountable to scientific and medical values.
Why Labs Request Clinical Information: Examining the Impact on Patient Care
Tuesday, July 30, 2:00 p.m.
Director, Genetics Division
Co-Medical Director, Pharmacogenomics
Co-Director, Clinical Molecular Genetics Fellowship Program
Use of genetic testing is increasing across all areas of medicine. However, test-ordering errors can adversely impact patient care and increase costs to patients and hospitals. Test-results interpretation can be improved by understanding clinical context. This presentation will utilize case examples to illustrate the necessity for collaboration between the clinician and the laboratory so that the best patient care at the lowest cost can be provided.
What’s in a Number? Can Quantitative Drug Testing Results Be Used to Delineate Partial vs. Full Dose Compliance?
Wednesday, July 31, 11:00 a.m.
Medical Director, Toxicology
Co-Medical Director, Pharmacogenetics
Urine drug testing is a useful tool for evaluating adherence to prescribed medication, particularly in pain management. For some drugs, such as opioids, quantitative results help define the patient phenotype and guide interpretation of adherence, but can be over-interpreted. This presentation will focus on using quantitative results to evaluate drug adherence vs. estimating adherence to a specific dose of a drug.
Children Aren’t Small Adults (and Other Pediatric Reference Interval Challenges)
Wednesday, July 31, 2:00 p.m.
Medical Director, Endocrinology
Establishing reference values that accurately encompass an entire population can be difficult, and specimens from healthy individuals are especially difficult to obtain. ARUP has been at the forefront of building a specimen repository from healthy children aged 6 months to 18 years since 2002. This presentation will discuss the complexities associated with establishing pediatric reference intervals, the limitations of current approaches, and the value of using well characterized sample repositories for this purpose.
Posters & Presenters
Kushnir MM, La'ulu SL, Ray JA, Rockwood AL, Rawlins ML, Meikle AW, Straseski JA—Poster
Kushnir MM, La'ulu SL, Greer R, Ray JA, Rockwood AL, Rawlins ML, Meikle AW, Straseski JA. Age and gender-related variation in concentrations of cortisol, cortisone and cortisol/cortisone ratio.
Liu A, Longo N, Pasquali M—Poster
Liu A, Alston M, Guymon R, Longo N, Pasquali M. Analysis of urinary succinylacetone by UPLC-MS/MS for monitoring of patients with tyrosinemia type I.
Hackenmueller SA, Strathmann FG. Clinical and analytical performance of total and fractionation assays for urine arsenic.
La'ulu SL, Kushnir MM, Rawlins ML, Ray JA, Roberts WL, Straseski JA—Poster
Greer RW, La'ulu SL, Kushnir MM, Rawlins ML, Ray JA, Roberts WL, Straseski JA. Cortisol Values in critically ill patients: Comparison of six automated immunoassays to LC-MS/MS.
Lu J, Grenache DG—Poster
Lu J, Pulsipher B, Grenache DG. Development of an enzymatic assay to measure lactate in perchloric acid-precipitated whole blood.
McMillin GA. Genetic associations in pain management and how they might apply to drug selection. (Short Course 73122)
Barakauskas VE, Wright C, Hammerstrom TB, Bradshaw TA, Johnson-Davis KL, Lehman CM. Improving turn-around-times for immunosuppressant drug monitoring at a university hospital through process optimization.
Merrigan SD, Straseski JA—Poster
Merrigan SD, Yang DT, Straseski JA. Intrinsic factor blocking antibody interference is not detected in five automated cobalamin immunoassays.
Rule GS, Wilson AR, Rockwood AL—Poster
Rule GS, Ohman TL, Carlisle HJ, Wilson AR, Rockwood AL. LC/MS quantitation without the use of full, batch-wise calibration sets.
Juenke JM, Johnson-Davis KL—Poster
Juenke JM, Brown PI, Johnson-Davis KL. Methanol quantitation: evaluating the CATACHEM methanol enzymatic assay on an AU400e.
La’ulu SL, Tebo AE, Straseski JA—Poster
La’ulu SL, Suh-Lailam BB, Davis KW, Tebo AE, Straseski JA. Performance characteristics of The NGAL Test™ using the Roche Cobas c501 analyzer.
Erickson JA, Grenache DG—Poster
Erickson JA, Van De Walle TL, Grenache DG. Performance evaluation of a monoclonal based fecal calprotectin ELISA and comparison with an established assay.
La'ulu SL, Wilson AR, Straseski JA, Tebo AE—Poster
La'ulu SL, Suh-Lailam BB, Davis KW, Wilson AR, Straseski JA, Tebo AE. Profiling neutrophil gelatinase-associated lipocalin (NGAL) and other biomarkers in suspected systemic lupus erythematosus patients.
Suh-Lailam BB, Carlisle H, Ohman T, McMillin GA. Reference interval determination for anabasine in urine: a biomarker of active tobacco use.
Wyness SP, La'ulu SL, Straseski JA—Poster
Wyness SP, La'ulu SL, Yee M, Tosiello L, Straseski JA. The method matters: multiple macroenzymes detected in the presence of hypergammaglobulinemia.
Lu J, Grenache, DG—Poster
Lu J, Clinton S, Grenache DG. Validation of an automated immunoassay for the quantitative measurement of hemoglobin in stool.